Industry News

Bristol Myers Squibb has launched Clear Understanding, a campaign featuring patients living with moderate to severe plaque psoriasis who are sharing what it’s really like for them to live with the disease from dealing with symptoms to navigating relationships with friends, family or co-workers to dispelling misconceptions about the condition.

Novartis announced that it has completed its acquisition of Chinook Therapeutics, Inc., a Seattle, WA, based biopharmaceutical company focused on the discovery, development, and commercialization of precision medicines for kidney diseases, in a transaction valued at up to USD 3.5 billion.

The Central Drugs Standard Control Organisation along with state licensing authorities has conducted risk-based inspections of 162 pharmaceutical firms and issued show-cause notices in 143 cases, Union Health minister Mansukh Mandaviya said on Tuesday.

Eli Lilly and Company announced the successful completion of its acquisition of DICE Therapeutics, Inc  The acquisition expands Lilly's immunology portfolio to include DICE's novel oral therapeutic candidates, including oral IL-17 inhibitors currently in clinical development, to treat chronic diseases in immunology.

Intas launches of Topical TOFATAS – a DCGI-approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above having flare-ups of the disease.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The National Institutes of Health launched and is opening enrollment for phase 2 clinical trials that will evaluate at least four potential treatments for long COVID, with additional clinical trials to test at least seven more treatments expected in the coming months. Treatments will include drugs, biologics, medical devices and other therapies. The trials are designed to evaluate multiple treatments simultaneously to identify more swiftly those that are effective.

Glenmark Pharmaceuticals Ltd. is an integrated, research‐led, global pharmaceutical company, with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.

Tarsus Pharmaceuticals, Inc, whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced that the U.S. Food and Drug Administration (FDA) approved XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. XDEMVY, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause of Demodex blepharitis.